Email Alerts

Data or Dollars

In our continuing quest to educate we thought it best to provide some perspective on the difference between drugs and devices when it comes to investing. We felt this was timely as recently we have seen more money flow into the CGM wannabe arena. Now in the interest of fairness we shall not provide the names of the companies which received money, nor will we embarrass the fools who invested...

An upside-down Unicorn

It’s not often that we get to be right twice about anything so on these rare occasions, these Unicorn events Momma Kliff said it’s ok to brag. Yesterday Teladoc closed below $140 and continues to fall today. Since March 24, 2020, the stock has fallen over 17% over that same time span the S&P 500 has DOUBLED. Since February 15 of this year the stock has fallen almost 50% and...

The pink elephant with polka dots

Before I begin today this is one post, I will encourage you to share as I truly hope to prompt a debate with a somewhat controversial point of view. Not like we have shied away from taking controversial positions in the past, but this the subject matter has nothing to do with the industry of diabetes rather the patients themselves. We call this the pink elephant with polka dots as...

Which story is it?

Looking over the results and reading the transcript we can’t exactly figure out which story goes with Senseonics. Is it the little engine that could as it remains around despite very difficult odds? Or is Senseonics Dead Man Walking? Just look at some of things said yesterday: “Through the first half of the year, the global commercial partnership integration has progress to Ascensia taking full commercial operations, and we have collaboratively...

Becoming clearer everyday

First, we owe an apology to the folks at Tandem who reported solid earnings last week and we missed the call. Now we’re not sure how that happened and contrary to rumors happy hour had nothing to do with this. We’d like to promise that this won’t happen again, but Momma Kliff told us never to make a promise you are not sure you can keep. So, let’s say we...

The Street is WRONG

Let’s get to the point quickly today as it is Friday and I know everyone wants to get an early start on the weekend– the street is dead wrong about Insulet and any sell off in the stock is a great opportunity for investors to jump in. While we didn’t listen to the call, we did read the transcript and nothing the company said was unexpected that is if people...

Guess what day it is

Before we get started with an analysis of the results released by Novo Nordisk it’s appropriate that slide deck used by the company ran 138 slides. Keep in mind this is not full year results but quarterly results – this is so damn Novo. Just as Lilly is focused on GLP-1 sales Novo too is now GLP-1 first insulin second. Just look at this from their earnings announcement “Sales of GLP-1 diabetes...

Numbers don’t lie

Not like we needed even more evidence that Lilly is now a GLP-1 first insulin second company here are some numbers from today’s earnings release all of which are year to date sales Trulicity $2.98 Billion Humalog $1.2 Billion Humulin $637 million Basaglar $457 million Sales of the three insulin products added together still do not match what Trulicity is doing. Want more reasons why GLP-1’s are getting all the attention and not just because...

Will it matter

This week both Lilly and Novo Nordisk report earnings and while they are still in the insulin business insulin is no longer their bread-and-butter product. Yes, they still sell a ton of insulin but when it comes to making money GLP-1’s is what drives profits. The fact is these two legacy diabetes companies are now GLP-1 first and insulin second. Insulin for all practical purposes has become a commodity. Now in...

Lots to chew on

Just when you think there’s nothing new to say about Dexcom along comes something fresh. Yesterday we expected a typical Dexcom earnings call, blow past the number, raise guidance, and fend off questions on how Libre is going to rule the world. These calls have become predictable and frankly dull. Yesterday was a different story as the company gave investors a lot to chew on and think about. Now based...